Seonhui Shim Immunology/Oncology Stem Cell Scientist

Expertise

Immunology/Oncology Stem Cell Scientist

Stem Cells

iPSC, ES, HSC, UCB

Gene Editing

CRISPR, TALEN, KO, KI

Non-viral Gene Delivery

Therapeutic Antibodies

Bispecific Antibodies

NK Immunology

Tumor Microenvironment

NK Cell Cross-talk

Experience

Thermofisher Scientific - Scientist III

  • Carlsbad, California
  • 2021 March - Present

Genome edited stem cell therapy: CRISPR/TALEN genome editing in iPSCs. Model establishment for off-the-shelf cell therapy. Non-viral gene-editing in iPSCs.

University of Colorado - Postdoctoral Fellow

  • Aurora, Colorado
  • 2016 - 2021

Making “off the shelf” blood cells: Epigenetically modulated ESC/iPSCs enhanced expansion of hematopoietic stem cells and increased efficacy of bone marrow transplantation, which can differentiate to multi-lineage blood cells including NK cells.

NK cell therapy in tumor microenvironmet: Defining genes and subtypes of tumor infiltrating NK cells by RNA-seq and etc. for NK cell therapy: which can be used for NK-CAR.

Understanding trajectory of ILCs : Identifying innate lymphocyte cells’(ILC) trajectory after making epigenetic regulation of ES/iPS derived HSC

Samsung Electronics (Samsung Advanced Institute of Technology) - Staff Scientist

  • Seoul, South Korea
  • 2010 - 2016

Therapeutic antibody project

  • Biomarker study: developing predictive/pharmacodynamic marker of therapeutic c-MET antibody (three US patents). 95% prediction accuracy.
  • Mechanism study: cellular function of the therapeutic antibody (one publication), combinational therapies for therapeutic antibody
  • Patient derived xenograft study (PDX): designing PDX study or xenograft model, time course xenograft model for biomarker.
  • Analysis: patients' or xenografts' serum analysis (ex. PK, ADA, soluble marker), patients' tissue analysis (IHC), mutation analysis focusing on translation research to find targeted patients’ population.

Bi-specific antibody project

  • Development of bi-specific antibodies: selection of cancer target to develop bi-specific antibodies, manufacturing new bi-specific antibody platform.
  • Functional study of bi-specific antibodies: binding test by ELISA or Biacore, cell efficacy test, design of in vivo experiments for bi-specific antibodies

Cell penetrating protein project

  • Developing novel protein cancer-therapeutics in use of cell penetrating (CPP) system loaded p53p18; analysis or functional study p53p18 delivery (Immunofluorescence, FACS, Western), mechanism study of p53p18 chimera protein

Education

Doctor of Philosophy

  • Seoul National University, Seoul, South Korea
  • 2006 - 2009

Thesis: “Combining gene therapy using conditionally replicating adenovirus (CRAd) and ad-TRAIL in head and neck cancer cell lines.”

Master of Science

  • Seoul National University, Seoul, South Korea
  • 2004 - 2006

Thesis: “The role of STAT1 in tumor killing induced by STAT3 inhibition of head and neck carcinoma cell lines”

Bachelor of Science

  • Hanyang University, Seoul, South Korea
  • 2001 - 2003

Publications

HDAC Inhibitors Enhance Embryonic Stem Differentiation into Hematopoietic Stem Cells by Using Hemogenic Endothelium.

Seonhui Shim, Renee Woods, Tyler Shank, Ashley M. Yingst, Dejene M. Tufa, Kenneth Jones, Michael R. Verneris.

Accepted in Stem cell Translational Medicine.

Human Innate Lymphoid Cell Precursors Express CD48 that Modulates ILC Differentiation through 2B4 Signaling.

Dejene M. Tufa, Tyler Shank, Ashley M. Yingst, George Devon Trahan, Seonhui Shim, Jessica Lake, Renee Woods, Kenneth Jones and Michael R. Verneris.

2020 Science Immunology

Prolactin Acts on Early Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage.

Dejene M. Tufa, Tyler Shank, Ashley M. Yingst, George Devon Trahan, Seonhui Shim, Jessica Lake, Renee Woods, Kenneth Jones and Michael R. Verneris.

2020 Scientific Reports

CD48 Marks the Human Common Helper ILC Precursor (CHILP) and Controls ILC Differentiation.

Dejene M. Tufa, Ashley M. Yingst, Tyler Shank, Seonhui Shim, Jessica Lake, Renee Woods, Kenneth Jones and Michael R. Verneris.

2019 Frontier immunology

Transient Expression of GATA3 in Hematopoietic Stem Cells Facilitates Helper Innate Lymphoid Cell Differentiation.

Dejene M. Tufa, Ashley M. Yingst, Tyler Shank, Seonhui Shim, Jessica Lake, Renee Woods, Michael R. Verneris.

Frontiers Immunology 2019 March

Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells.

Mathew G. Angelos, Paige N. Ruh, Beau R. Webber, Robert H. Blum, Caitlin D. Ryan, Laura Bendzick, Seonhui Shim, Ashley M. Yingst, Dejene M. Tufa, Michael R. Verneris, Dan S. Kaufman.

Blood. 2017

Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.

JM Lee, SH Lee, J-W Hwang, SJ Oh , B Kim , S Jung , S-h Shim , PW Lin , SB Lee , M-Y Cho , YJ Koh , SY Kim , S Ahn , J Lee , K-m Kim , KH Cheong , J Choi and K-A Kim.

Oncogene. 2016 February

USP8 modulates ubiquitination of LRIG1 for MET degradation.

Oh YM, Lee SB, Choi JH, Suh HY, Shim SH, Song YJ, Kim BG, Lee JM, Jeong YJ, Cheong KH, Song P H, Kim KA.

Scientific Report. 2014 May 15;4:4980

Cancer associated fibroblasts (CAF) expressing CD44 high increased the aggressiveness of cancer cells.

Shim SH, Hah JH, Cho SY, Kim TM, Koh YI, Kim DW, Heo DS, Sung MW. Korean Journal of Head & Neck Oncology.

2014 October v30 p43-52.

Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.

Kim DR, Park MY, Lee CS, Shim SH, Yoon HI, Lee JH, Sung MW, Kim YS, Lee CT.

Cancer Gene Ther. 2011 Jul;18(7):467-77

A combination treatment with SAHA and ad-p63/p73 shows an enhanced anti-cancer effect in HNSCC.

Shim SH, Lee CT, Hah JH, Lee JJ, Heo DS, Sung MW.

Tumour Biol. 2010 Dec;31(6):659-66

Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line.

Shim SH, Hah JH, Hwang SY, Heo DS, Sung MW. Oncology Reports.

2010 Apr;23(4):1139-43

Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.

Oh JY, Park MY, Kim DR, Lee JH, Shim SH, Chung JH, Yoon HI, Lee JH, Sung MW, Kim YS, Lee CT.

Int J Mol Med. 2010 Mar;25(3):369-76.

Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in HNSCC.

Shim SH, Lee CT, Hah JH, Lee JJ, Park SW, Heo DS, Sung MW.

Cancer Science. 2009 Oct, 101(2):482-487.

Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines.

Shim SH, Sung MW, Park SW, Heo DS.

Int J Mol Med. 2009 Jun;23(6):805-10.

Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines.

Park SW, Sung MW, Heo DS, Inoue H, Shim SH, Kim KH.

Oncogene. 2005 Oct 6;24(44):6689-98.

Patents

COMPOSITIONS, METHODS AND USES FOR IMPROVED PRODUCTION OF HEMATOPOIETIC STEM CELLS (HSCS).

U.S. 63/007,664

Prediction of effect of a c-met inhibitor using mutation of KRAS or BRAF.

KR14-0130560, US20160090635A1

Combination therapy using c-met inhibitor and IGF-1R inhibitor.

KR14-0163792, US20160144027A1

Biomarker for predicting or monitoring efficacy of c-met inhibitor.

EP15150360, CN20150008065.5 KR14-0001799, US20150192588A1

Heterodimeric bi-specific anti-cMET/anti-Her2 antibodies.

KR13-0033874

Heterodimeric bi-specific anti-cMET/anti-Ang2 antibodies.

KR13-0073820

Composition for combination therapy comprising anti-her2 antibody and anti-c-met antibody.

PCT/KR2014/004672/ US20170233489A1

Protein complexes and methods of manufacturing bi-specific antibodies using the protein complex.

US14/023538 KR12-100649 EP13183787.4

Awards / Grants

Gates Grubstake Research Grant (2018), $350,000

Generation of Engraftable Hematopoietic Stem Cells From iPS/ES stem cells

Samsung Best Paper Awards (2012)

Antitumor effect of tumor suppressor p53p18 chimeric protein with intracellular trafficking.

Young Scientist Awards (2010)

The 4th World Congress of International Federation of Head and Neck Oncologic Societies, Seoul, Korea.